Butyrate, a SCFA from fiber fermentation, slows digestion and increases GLP-1 production (Huber et al, 2024
The SNAC absorption enhancer in each tablet needs an empty stomach to work properly
While only 1 in 5 Americans said these medications have changed their view of what a healthy body looks like, for most, the changes were positive: 14% said they now see more body types as "healthy", while just 6% still viewed leanness as the standard
These lipid modifications extend the drugs half-life and improve pharmacokinetic behavior in the body
Seven drugs have currently been approved for the treatment of Type 2 diabetes mellitus, including short-acting agents like exenatide and lixisenatide, as well as long-acting injectable agents such as albiglutide, dulaglutide, liraglutide, and semaglutide. GLP-1s regulate lipid metabolism, reducing the effects of hyperlipidemia and helping to lower the risk for both chronic kidney disease (CKD) and diabetic kidney disease. They have also been shown to reduce oxidative stress, which includes stimulating glomerular filtration and reducing vasoconstriction, slowing the progression of CKD. Limited data from clinical trials have been published on the effects of GLP-1 receptor agonists in individuals with post-liver transplant diabetes mellitus (PTDM)
